Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07358195 · ClinicalTrials.gov registry record · Early Phase 1
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT07358195: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07358195 is a Early Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07358195, a Early Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetoclax.
Interventions
- DRUG Venetoclax
- PROCEDURE Hematopoietic Cell Transplantation
- PROCEDURE Kidney Transplant
- PROCEDURE Hematopoietic Cell Transplantation Conditioning Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2026-07 |
| Est. Completion | 2029-12 |
| Phase | Early Phase 1 |
What is known before NCT07358195 opens enrollment
NCT07358195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT07358195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07358195 about?
NCT07358195 is a clinical study titled "Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation". The primary objective is to assess the safety of the addition of venetoclax to reduced intensity conditioning for HLA-matched and haploidentical combined HSC and kidney transplantation as measured by stable full donor hematopoiesis and absence of CTCAE grade IV or V toxicity attributable to venetocl...
What is the current status of trial NCT07358195?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2026-07. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07358195?
The interventions under investigation include: Venetoclax (DRUG), Hematopoietic Cell Transplantation (PROCEDURE), Kidney Transplant (PROCEDURE), Hematopoietic Cell Transplantation Conditioning Regimen (PROCEDURE).
Who is sponsoring clinical trial NCT07358195?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07358195's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia